设为首页  |   加入收藏

林凡


发布时间: 2016-03-24 访问次数: 998

   

林凡士,教授,博士生导师

    

研究方向:肿瘤小分子靶向药物的个性化治疗

地址:江苏南京市龙眠大道101号学海楼A111

邮编:210029

手机:18120163329

电话:025-86869472  

邮件:linfan@njmu.edu.cn


林凡博士,教授,博士生导师。2016年作为引进教授受聘于南京医科大学细胞生物学系。浙江大学生物学学士。分别于2006年和2013年获阿姆斯特丹大学医学生物化学硕士和荷兰癌症研究所博士学位。20132015年在新加坡国立大学医学院从事博士后研究。期间获Amsterdam Merit奖学金,并作为共同申请人成功申请荷兰Stop Hersentumoren Foundation基金一项。近来主要的研究方向为肿瘤小分子靶向药物的个性化治疗。近年来在Clin Cancer Res,Int J Cancer,Eur J Cancer等国际癌症期刊发表论文10余篇。 

科研领域及专长:

  1. 针对关键癌症基因突变的小分子靶向药物筛选以及用基于合成致死原理的功能基因组学方法筛选新药靶点。

  2. 体内,体外临床前恶性肿瘤实验模型(包括肿瘤异源移植模型以及自发肿瘤模型)的建立;

  3. 肿瘤药物药动,药代(PD/PK)以及血脑屏障药物转运蛋白在限制小分子药物递送至中枢神经系统肿瘤的角色的研究。

  4. 肿瘤信号通路分析。

 

发表文献

(1) Lin, F., et al., Proteomic profiling predicts drug response to novel targeted anticancer therapeutics. Expert Rev Proteomics, [Epub ahead of print] 2016.

(2) Lin F, Tan H. J., Guan J. S., and Lim Y. P. Divide and conquer: subproteomic approaches toward gastric cancer biomarker and drug target discovery. Expert Rev Proteomics. 2014 Mar 31. 2014114):515-530

(3) Lin F, de Gooijer MC, Moreno Roig E, Buil L, Christner SM, Beumer JH, Wurdinger T, Beijnen JH, van Tellingen O. ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. 2014,20(10):2703-2713

(4) Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, Schinkel AH. OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice. Mol Cancer Ther. 2013,133(5):1222-1233

(5) Lin F, Beijnen JH, van Tellingen O. Targeting on Core (Mutated) Pathways of High-grade Gliomas: Challenges of Intrinsic Resistance and Drug Efflux Transporters. CNS Oncology 2:3, 271-288.

(6) Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O. Abcc4 together with Abcb1 and Abcg2 form a robust co-operative drug efflux system that restricts the brain entry of camptothecin analogs. Clin Cancer Res. 2013 Apr 15;19(8):2084-95.

(7) Lin F, Hogendijk H, Beijnen JH, van Tellingen O. Sildenafil is not a useful inhibitor of ABCB1 and ABCG2 in vivo. Eur J Cancer. 2013 May;49(8):2059-64. doi: 10.1016/j.ejca.2012.12.028.

(8) Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the Blood-Brain Barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.

(9) Lin F, Chandrasekaran G, de Gooijer MC, Beijnen JH, van Tellingen O. Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012;901:9-17

(10) Lin F, Sherris D, Beijnen JH, van Tellingen O. High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3823-31.

(11)  Lagas JS, Lin F, Wagenaar E, Vlaming ML, van Tellingen O, Beijnen JH, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 2010;16:130-40.

(12)  Qu B, Xu A, Zhao YM, Lin F, Wei XD, Hong WS. Clinical Analysis of 243 Patients with Vitiligo and the Association with HLA-DQBI. Chin J Dermatol, 2003; 36:693-695

 

 

 

  版权所有© 南京医科大学基础医学院
  Tel:025-86862876 Fax:025-86862912